Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial | Synapse
March 3, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial
Key Points
Patient-reported outcomes revealed significant improvements with durvalumab compared to placebo in small-cell lung cancer treatment.
The results showed a notable enhancement in quality of life metrics—highlighting the benefits of durvalumab.
Observational analysis conducted after concurrent chemoradiotherapy to assess treatment effects on patients' experiences and quality of life.
This trial emphasizes the importance of integrating patient-reported outcomes in assessing the efficacy of cancer treatments.